1-苄基-4-[2-(三氟甲基)苯基]哌啶-4-醇 | 208989-32-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-苄基-4-[2-(三氟甲基)苯基]哌啶-4-醇
• 英文名称: 1-benzyl-4-(2-(trifluoromethyl)phenyl)piperidin-4-ol
• 英文别名: 1-benzyl-4-hydroxy-4-(2-tri-fluoromethylphenyl)piperidine；1-Benzyl-4-[2-(trifluoromethyl)phenyl]piperidin-4-ol
• CAS: 208989-32-6
• 化学式: C₁₉H₂₀F₃NO
• 分子量: 335.369
• InChiKey: YFVBEBRJPYXQLL-UHFFFAOYSA-N

物化性质

• 沸点：
  431.1±45.0 °C(Predicted)
• 密度：
  1.247±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-苄基-4-[2-(三氟甲基)苯基]哌啶-4-醇 在 氯化亚砜 、 palladium 10% on activated carbon 、 甲酸铵 作用下， 以 甲醇 为溶剂， 反应 4.0h， 生成 4-[2-(三氟甲基)苯基]哌啶
  参考文献：
  名称：

  [EN] 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE
  [FR] 4-PHÉNYLPIPÉRIDINES, LEUR PRÉPARATION ET LEUR UTILISATION

  摘要：

  本发明提供一种具有以下结构的化合物：(结构表示)其中R1、R2、R3、R4和R5分别独立地为H、卤素、CF3或C1-C4烷基；R6为H、OH或卤素；B为取代或未取代的杂环、吡啶并[1,2-a]嘧啶、吡唑并[1,2-a]嘧啶、噻二唑或三唑，其中该杂环不是氯取代的吲哚；当取代时，吡唑除三氟甲基外还取代其他官能团，或其药学上可接受的盐。

  公开号：

  WO2014152013A1
• 作为产物：
  描述：

  N-苄基哌啶酮 在 magnesium 、 氯化铵 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 3.83h， 生成 1-苄基-4-[2-(三氟甲基)苯基]哌啶-4-醇
  参考文献：
  名称：

  Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof

  摘要：

  该发明涉及一般式(I)的取代1-哌嗪基酰基哌啶衍生物，其中：n为1或2；p为1或2；R1代表卤原子；三氟甲基基团；(C1-C4)烷基；(C1-C4)烷氧基；三氟甲氧基基团；R2代表氢原子或卤原子；R3代表氢原子；—OR5基团；—CH2OR5基团；—NR6R7基团；—NR8COR9基团；—NR8CONR10R11基团；—CH2NR12R13基团；—CH2NR8CONR14R15基团；(C1-C4)烷氧羰基；—CONR16R17基团；或者R3构成与其连接的碳原子和哌啶环的相邻碳原子之间的双键；R4代表从中选择的芳香族基：所述芳香族基未取代或者经过单取代或双取代，取代基独立选择自卤原子；(C1-C4)烷基；(C1-C4)烷氧基；三氟甲基基团；制备方法和治疗应用。

  公开号：

  US20050176722A1

文献信息

• Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
  申请人：Bono Francoise

  公开号：US20050176722A1

  公开（公告）日：2005-08-11

  The invention relates to substituted 1-piperazinylacylpiperidine derivatives of general formula (I) in which: n is 1 or 2; p is 1 or 2; R 1 represents a halogen atom; a trifluoromethyl radical; a (C 1 -C 4 )alkyl; a (C 1 -C 4 )alkoxy; a trifluoromethoxy radical; R 2 represents a hydrogen atom or a halogen atom; R 3 represents a hydrogen atom; a group —OR 5 ; a group —CH 2 OR 5 ; a group —NR 6 R 7 ; a group —NR 8 COR 9 ; a group —NR 8 CONR 10 R 11 ; a group —CH 2 NR 12 R 13 ; a group —CH 2 NR 8 CONR 14 R 15 ; a (C 1 -C 4 )alkoxycarbonyl; a group —CONR 16 R 17 ; or else R 3 constitutes a double bond between the carbon atom to which it is attached and the adjacent carbon atom of the piperidine ring; R 4 represents an aromatic group selected from: the said aromatic groups being unsubstituted or being mono- or disubstituted by a substituent selected independently from a halogen atom; a (C 1 -C 4 )alkyl; a (C 1 -C 4 )alkoxy; a trifluoromethyl radical; Preparation process and therapeutic application.

  该发明涉及一般式(I)的取代1-哌嗪基酰基哌啶衍生物，其中：n为1或2；p为1或2；R1代表卤原子；三氟甲基基团；(C1-C4)烷基；(C1-C4)烷氧基；三氟甲氧基基团；R2代表氢原子或卤原子；R3代表氢原子；—OR5基团；—CH2OR5基团；—NR6R7基团；—NR8COR9基团；—NR8CONR10R11基团；—CH2NR12R13基团；—CH2NR8CONR14R15基团；(C1-C4)烷氧羰基；—CONR16R17基团；或者R3构成与其连接的碳原子和哌啶环的相邻碳原子之间的双键；R4代表从中选择的芳香族基：所述芳香族基未取代或者经过单取代或双取代，取代基独立选择自卤原子；(C1-C4)烷基；(C1-C4)烷氧基；三氟甲基基团；制备方法和治疗应用。
• [EN] 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE<br/>[FR] 4-PHÉNYLPIPÉRIDINES, LEUR PRÉPARATION ET LEUR UTILISATION
  申请人：UNIV COLUMBIA

  公开号：WO2014152013A1

  公开（公告）日：2014-09-25

  The present invention provides a compound having the structure: (structurally represented) wherein R1, R2, R3, R4, and R5 are each independently H, halogen, CF3 or C1-C4 alkyl; R6 is H, OH, or halogen; B is a substituted or unsubstituted heterobicycle, pyridazine, pyrazole, pyrazine, thiadiazole, or triazole, wherein the heterobicycle is other than chloro substituted indole; and the pyrazole, when substituted, is substituted with other than trifluoromethyl, or a pharmaceutically acceptable salt theref.

  本发明提供一种具有以下结构的化合物：(结构表示)其中R1、R2、R3、R4和R5分别独立地为H、卤素、CF3或C1-C4烷基；R6为H、OH或卤素；B为取代或未取代的杂环、吡啶并[1,2-a]嘧啶、吡唑并[1,2-a]嘧啶、噻二唑或三唑，其中该杂环不是氯取代的吲哚；当取代时，吡唑除三氟甲基外还取代其他官能团，或其药学上可接受的盐。
• 11-Beta HSD 1 inhibitors
  申请人：Xiang Shaoyun Jason

  公开号：US20070219198A1

  公开（公告）日：2007-09-20

  This invention relates to inhibiting 11βHSD1.

  该发明涉及抑制11βHSD1。
• 1-Phenylalkyl-1,2,3,6-tetrahydropyridines for treating Alzheimer's
  申请人：Sanofi-Synthlabo

  公开号：US06034090A1

  公开（公告）日：2000-03-07

  The invention relates to compounds of the formula in which: Y is --CH-- or --N--; R.sub.1 is hydrogen, a halogen or a CF.sub.3, (C.sub.1 -C.sub.4)alkyl or (C.sub.1 -C.sub.4)alkoxy group; R.sub.2 is a methyl or ethyl group; R.sub.3 and R.sub.4 are each hydrogen or a (C.sub.1 -C.sub.3)alkyl; and X is: (a) a (C.sub.1 -C.sub.6)alkyl, a (C.sub.1 -C.sub.6)alkoxy, a (C.sub.3 -C.sub.7)carboxyalkyl, a (C.sub.1 -C.sub.4)alkoxy-carbonyl(C.sub.1 -C.sub.6)alkyl, a (C.sub.3 -C.sub.7)carboxyalkoxy or a (C.sub.1 -C.sub.4)alkoxycarbonyl-(C.sub.1 -C.sub.6)alkoxy; (b) a radical selected from (C.sub.3 -C.sub.7)cycloalkyl, (C.sub.3 -C.sub.7)cycloalkoxy, (C.sub.3 -C.sub.7)-cycloalkylmethyl, (C.sub.3 -C.sub.7)cycloalkylamino and cyclohexenyl, it being possible for said radical to be substituted by a halogen, hydroxyl, (C.sub.1 -C.sub.4)-alkoxy, carboxyl, (C.sub.1 -C.sub.4)alkoxycarbonyl, amino or mono- or di-(C.sub.1 -C.sub.4)-alkylamino; or (c) a group selected from a phenyl, phenoxy, phenylamino, N-(C.sub.1 -C.sub.3)alkyl-phenylamino, phenylmethyl, phenylethyl, phenylcarbonyl, phenylthio, phenylsulfonyl, phenylsulfinyl and styryl, it being possible for said group to be monosubstituted or polysubstituted on the phenyl group by a halogen, CF.sub.3, (C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkoxy, cyano, amino, mono- or di-(C.sub.1 -C.sub.4)alkyl-amino, (C.sub.1 -C.sub.4)acylamino, carboxyl, (C.sub.1 -C.sub.4)alkoxycarbonyl, aminocarbonyl, mono- or di-(C.sub.1 -C.sub.4)alkylaminocarbonyl, amino(C.sub.1 -C.sub.4)alkyl, hydroxy(C.sub.1 -C.sub.4)alkyl or halogeno(C.sub.1 -C.sub.4)alkyl; to a method of preparing them and to the pharmaceutical compositions containing them. These compounds have neurotrophic and neuroprotective activity.

  本发明涉及以下式的化合物：其中：Y为--CH--或--N--；R1为氢、卤素或CF3，(C1-C4)烷基或(C1-C4)烷氧基；R2为甲基或乙基基团；R3和R4分别为氢或(C1-C3)烷基；X为：(a) (C1-C6)烷基、(C1-C6)烷氧基、(C3-C7)羧基烷基、(C1-C4)烷氧基酰基(C1-C6)烷基、(C3-C7)羧酸烷氧基或(C1-C4)烷氧基卡宾酰基-(C1-C6)烷氧基；(b) 从(C3-C7)环烷基、(C3-C7)环烷氧基、(C3-C7)-环烷基甲基、(C3-C7)环烷基氨基和环己烯基中选择的基团，该基团可以被卤素、羟基、(C1-C4)烷氧基、羧基、(C1-C4)烷氧基酰基、氨基或单烷基或二烷基氨基取代；或(c) 选择自苯基、苯氧基、苯胺基、N-(C1-C3)烷基-苯胺基、苯甲基、苯乙基、苯羰基、苯硫醚基、苯磺酰基、苯磺酰亚基和苯乙烯基的基团，该基团可以被卤素、CF3、(C1-C4)烷基、(C1-C4)烷氧基、氰基、氨基、单烷基或二烷基氨基、(C1-C4)酰胺基、羧基、(C1-C4)烷氧基酰基、氨基酰基、单烷基或二烷基氨基酰基、氨基(C1-C4)烷基、羟基(C1-C4)烷基或卤代(C1-C4)烷基单取代或多取代于苯基上；以及制备它们的方法和含有它们的药物组合物。这些化合物具有神经营养和神经保护作用。
• Diphenylalkyl-tetrahydropyridines, process for their preparation, and
  申请人：Sanofi-Synthelabo

  公开号：US06124318A1

  公开（公告）日：2000-09-26

  The invention relates to compounds of the formula ##STR1## in which: Y is --CH-- or --N--; R.sub.1 is a halogen or a CF.sub.3, (C.sub.1 -C.sub.4)alkyl or (C.sub.1 -C.sub.4)alkoxy group; R.sub.2 and R.sub.3 are each hydrogen or a (C.sub.1 -C.sub.3)alkyl; n is 0 or 1; and Ph.sub.1 and Ph.sub.2 are each independently an unsubstituted, monosubstituted or polysubstituted phenyl group; to a process for their preparation and to the pharmaceutical compositions containing them. These compounds have neurotrophic and neuroprotective activity.

  本发明涉及公式##STR1##的化合物，其中：Y为--CH--或--N--; R.sub.1为卤素或CF.sub.3，(C.sub.1-C.sub.4)烷基或(C.sub.1-C.sub.4)烷氧基; R.sub.2和R.sub.3分别为氢或(C.sub.1-C.sub.3)烷基; n为0或1; Ph.sub.1和Ph.sub.2各自独立地为未取代，单取代或多取代的苯基; 以及包含它们的制药组合物。这些化合物具有神经营养和神经保护活性。